Table of Content

1 PD-1 and PD-L1 Inhibitor Market Overview
1.1 Product Overview and Scope of PD-1 and PD-L1 Inhibitor
1.2 PD-1 and PD-L1 Inhibitor Segment by Type
1.2.1 Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Type (2024-2034)
1.2.2 Monoclonal Antibody
1.2.3 Bispecific Antibody
1.3 PD-1 and PD-L1 Inhibitor Segment by Application
1.3.1 Global PD-1 and PD-L1 Inhibitor Market Value by Application: (2024-2034)
1.3.2 Lung Cancer
1.3.3 Stomach Cancer
1.3.4 Breast Cancer
1.3.5 Rectal Cancer
1.3.6 Others
1.4 Global PD-1 and PD-L1 Inhibitor Market Size Estimates and Forecasts
1.4.1 Global PD-1 and PD-L1 Inhibitor Revenue 2024-2034
1.4.2 Global PD-1 and PD-L1 Inhibitor Sales 2024-2034
1.4.3 Global PD-1 and PD-L1 Inhibitor Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 PD-1 and PD-L1 Inhibitor Market Competition by Manufacturers
2.1 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2024-2024)
2.2 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Manufacturers (2024-2024)
2.3 Global PD-1 and PD-L1 Inhibitor Average Price by Manufacturers (2024-2024)
2.4 Global PD-1 and PD-L1 Inhibitor Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Product Type & Application
2.7 PD-1 and PD-L1 Inhibitor Market Competitive Situation and Trends
2.7.1 PD-1 and PD-L1 Inhibitor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest PD-1 and PD-L1 Inhibitor Players Market Share by Revenue
2.7.3 Global PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 PD-1 and PD-L1 Inhibitor Retrospective Market Scenario by Region
3.1 Global PD-1 and PD-L1 Inhibitor Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global PD-1 and PD-L1 Inhibitor Global PD-1 and PD-L1 Inhibitor Sales by Region: 2024-2034
3.2.1 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2024-2024
3.2.2 Global PD-1 and PD-L1 Inhibitor Sales by Region: 2024-2034
3.3 Global PD-1 and PD-L1 Inhibitor Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2024-2034
3.3.1 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2024-2024
3.3.2 Global PD-1 and PD-L1 Inhibitor Revenue by Region: 2024-2034
3.4 North America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.4.1 North America PD-1 and PD-L1 Inhibitor Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034)
3.4.3 North America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.5.1 Europe PD-1 and PD-L1 Inhibitor Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034)
3.5.3 Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.6.1 Asia Pacific PD-1 and PD-L1 Inhibitor Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034)
3.6.3 Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.7.1 Latin America PD-1 and PD-L1 Inhibitor Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034)
3.7.3 Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa PD-1 and PD-L1 Inhibitor Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034)
3.8.3 Middle East and Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034)
4.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Type (2024-2024)
4.1.2 Global PD-1 and PD-L1 Inhibitor Sales by Type (2024-2034)
4.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2024-2034)
4.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034)
4.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2024)
4.2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Type (2024-2034)
4.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2024-2034)
4.3 Global PD-1 and PD-L1 Inhibitor Price by Type (2024-2034)
5 Segment by Application
5.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034)
5.1.1 Global PD-1 and PD-L1 Inhibitor Sales by Application (2024-2024)
5.1.2 Global PD-1 and PD-L1 Inhibitor Sales by Application (2024-2034)
5.1.3 Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2024-2034)
5.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034)
5.2.1 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2024)
5.2.2 Global PD-1 and PD-L1 Inhibitor Revenue by Application (2024-2034)
5.2.3 Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2024-2034)
5.3 Global PD-1 and PD-L1 Inhibitor Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Merck PD-1 and PD-L1 Inhibitor Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Bristol-Myers Squibb
6.2.1 Bristol-Myers Squibb Corporation Information
6.2.2 Bristol-Myers Squibb Description and Business Overview
6.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
6.2.5 Bristol-Myers Squibb Recent Developments/Updates
6.3 Pfizer
6.3.1 Pfizer Corporation Information
6.3.2 Pfizer Description and Business Overview
6.3.3 Pfizer PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Pfizer PD-1 and PD-L1 Inhibitor Product Portfolio
6.3.5 Pfizer Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Sanofi PD-1 and PD-L1 Inhibitor Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Regeneron Pharmaceuticals
6.5.1 Regeneron Pharmaceuticals Corporation Information
6.5.2 Regeneron Pharmaceuticals Description and Business Overview
6.5.3 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product Portfolio
6.5.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.6 Roche
6.6.1 Roche Corporation Information
6.6.2 Roche Description and Business Overview
6.6.3 Roche PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Roche PD-1 and PD-L1 Inhibitor Product Portfolio
6.6.5 Roche Recent Developments/Updates
6.7 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.4.4 AstraZeneca PD-1 and PD-L1 Inhibitor Product Portfolio
6.7.5 AstraZeneca Recent Developments/Updates
6.8 Bristol Myers Squibb
6.8.1 Bristol Myers Squibb Corporation Information
6.8.2 Bristol Myers Squibb Description and Business Overview
6.8.3 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product Portfolio
6.8.5 Bristol Myers Squibb Recent Developments/Updates
6.9 Hengrui Medicine
6.9.1 Hengrui Medicine Corporation Information
6.9.2 Hengrui Medicine Description and Business Overview
6.9.3 Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Hengrui Medicine PD-1 and PD-L1 Inhibitor Product Portfolio
6.9.5 Hengrui Medicine Recent Developments/Updates
6.10 Beigene
6.10.1 Beigene Corporation Information
6.10.2 Beigene Description and Business Overview
6.10.3 Beigene PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.10.4 Beigene PD-1 and PD-L1 Inhibitor Product Portfolio
6.10.5 Beigene Recent Developments/Updates
6.11 Innovent Biologics
6.11.1 Innovent Biologics Corporation Information
6.11.2 Innovent Biologics PD-1 and PD-L1 Inhibitor Description and Business Overview
6.11.3 Innovent Biologics PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.11.4 Innovent Biologics PD-1 and PD-L1 Inhibitor Product Portfolio
6.11.5 Innovent Biologics Recent Developments/Updates
6.12 Junshi Biosciences
6.12.1 Junshi Biosciences Corporation Information
6.12.2 Junshi Biosciences PD-1 and PD-L1 Inhibitor Description and Business Overview
6.12.3 Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Junshi Biosciences PD-1 and PD-L1 Inhibitor Product Portfolio
6.12.5 Junshi Biosciences Recent Developments/Updates
6.13 Akeso
6.13.1 Akeso Corporation Information
6.13.2 Akeso PD-1 and PD-L1 Inhibitor Description and Business Overview
6.13.3 Akeso PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Akeso PD-1 and PD-L1 Inhibitor Product Portfolio
6.13.5 Akeso Recent Developments/Updates
6.14 Alphamab Oncology
6.14.1 Alphamab Oncology Corporation Information
6.14.2 Alphamab Oncology PD-1 and PD-L1 Inhibitor Description and Business Overview
6.14.3 Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales, Revenue and Gross Margin (2024-2024)
6.14.4 Alphamab Oncology PD-1 and PD-L1 Inhibitor Product Portfolio
6.14.5 Alphamab Oncology Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 PD-1 and PD-L1 Inhibitor Industry Chain Analysis
7.2 PD-1 and PD-L1 Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 PD-1 and PD-L1 Inhibitor Production Mode & Process
7.4 PD-1 and PD-L1 Inhibitor Sales and Marketing
7.4.1 PD-1 and PD-L1 Inhibitor Sales Channels
7.4.2 PD-1 and PD-L1 Inhibitor Distributors
7.5 PD-1 and PD-L1 Inhibitor Customers
8 PD-1 and PD-L1 Inhibitor Market Dynamics
8.1 PD-1 and PD-L1 Inhibitor Industry Trends
8.2 PD-1 and PD-L1 Inhibitor Market Drivers
8.3 PD-1 and PD-L1 Inhibitor Market Challenges
8.4 PD-1 and PD-L1 Inhibitor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global PD-1 and PD-L1 Inhibitor Market Competitive Situation by Manufacturers in 2022
Table 4. Global PD-1 and PD-L1 Inhibitor Sales (K Units) of Key Manufacturers (2024-2024)
Table 5. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Manufacturers (2024-2024)
Table 6. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market PD-1 and PD-L1 Inhibitor Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of PD-1 and PD-L1 Inhibitor, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Product Type & Application
Table 12. Global Key Manufacturers of PD-1 and PD-L1 Inhibitor, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global PD-1 and PD-L1 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Inhibitor as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global PD-1 and PD-L1 Inhibitor Sales by Region (2024-2024) & (K Units)
Table 18. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2024-2024)
Table 19. Global PD-1 and PD-L1 Inhibitor Sales by Region (2024-2034) & (K Units)
Table 20. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2024-2034)
Table 21. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2024-2024)
Table 23. Global PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2024-2034)
Table 25. North America PD-1 and PD-L1 Inhibitor Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2024) & (K Units)
Table 27. North America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 28. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe PD-1 and PD-L1 Inhibitor Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2024-2024) & (K Units)
Table 32. Europe PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 33. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2024-2024) & (K Units)
Table 37. Asia Pacific PD-1 and PD-L1 Inhibitor Sales by Region (2024-2034) & (K Units)
Table 38. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2024) & (K Units)
Table 42. Latin America PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 43. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa PD-1 and PD-L1 Inhibitor Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa PD-1 and PD-L1 Inhibitor Sales by Country (2024-2024) & (K Units)
Table 47. Middle East & Africa PD-1 and PD-L1 Inhibitor Sales by Country (2024-2034) & (K Units)
Table 48. Middle East & Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa PD-1 and PD-L1 Inhibitor Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global PD-1 and PD-L1 Inhibitor Sales (K Units) by Type (2024-2024)
Table 51. Global PD-1 and PD-L1 Inhibitor Sales (K Units) by Type (2024-2034)
Table 52. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2024-2024)
Table 53. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Type (2024-2034)
Table 54. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Type (2024-2024)
Table 55. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Type (2024-2034)
Table 56. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2024-2024)
Table 57. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Type (2024-2034)
Table 58. Global PD-1 and PD-L1 Inhibitor Price (US$/Unit) by Type (2024-2024)
Table 59. Global PD-1 and PD-L1 Inhibitor Price (US$/Unit) by Type (2024-2034)
Table 60. Global PD-1 and PD-L1 Inhibitor Sales (K Units) by Application (2024-2024)
Table 61. Global PD-1 and PD-L1 Inhibitor Sales (K Units) by Application (2024-2034)
Table 62. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2024-2024)
Table 63. Global PD-1 and PD-L1 Inhibitor Sales Market Share by Application (2024-2034)
Table 64. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Application (2024-2024)
Table 65. Global PD-1 and PD-L1 Inhibitor Revenue (US$ Million) by Application (2024-2034)
Table 66. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2024-2024)
Table 67. Global PD-1 and PD-L1 Inhibitor Revenue Market Share by Application (2024-2034)
Table 68. Global PD-1 and PD-L1 Inhibitor Price (US$/Unit) by Application (2024-2024)
Table 69. Global PD-1 and PD-L1 Inhibitor Price (US$/Unit) by Application (2024-2034)
Table 70. Merck Corporation Information
Table 71. Merck Description and Business Overview
Table 72. Merck PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Merck PD-1 and PD-L1 Inhibitor Product
Table 74. Merck Recent Developments/Updates
Table 75. Bristol-Myers Squibb Corporation Information
Table 76. Bristol-Myers Squibb Description and Business Overview
Table 77. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitor Product
Table 79. Bristol-Myers Squibb Recent Developments/Updates
Table 80. Pfizer Corporation Information
Table 81. Pfizer Description and Business Overview
Table 82. Pfizer PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Pfizer PD-1 and PD-L1 Inhibitor Product
Table 84. Pfizer Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Sanofi PD-1 and PD-L1 Inhibitor Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Regeneron Pharmaceuticals Corporation Information
Table 91. Regeneron Pharmaceuticals Description and Business Overview
Table 92. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Regeneron Pharmaceuticals PD-1 and PD-L1 Inhibitor Product
Table 94. Regeneron Pharmaceuticals Recent Developments/Updates
Table 95. Roche Corporation Information
Table 96. Roche Description and Business Overview
Table 97. Roche PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Roche PD-1 and PD-L1 Inhibitor Product
Table 99. Roche Recent Developments/Updates
Table 100. AstraZeneca Corporation Information
Table 101. AstraZeneca Description and Business Overview
Table 102. AstraZeneca PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. AstraZeneca PD-1 and PD-L1 Inhibitor Product
Table 104. AstraZeneca Recent Developments/Updates
Table 105. Bristol Myers Squibb Corporation Information
Table 106. Bristol Myers Squibb Description and Business Overview
Table 107. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Bristol Myers Squibb PD-1 and PD-L1 Inhibitor Product
Table 109. Bristol Myers Squibb Recent Developments/Updates
Table 110. Hengrui Medicine Corporation Information
Table 111. Hengrui Medicine Description and Business Overview
Table 112. Hengrui Medicine PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Hengrui Medicine PD-1 and PD-L1 Inhibitor Product
Table 114. Hengrui Medicine Recent Developments/Updates
Table 115. Beigene Corporation Information
Table 116. Beigene Description and Business Overview
Table 117. Beigene PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. Beigene PD-1 and PD-L1 Inhibitor Product
Table 119. Beigene Recent Developments/Updates
Table 120. Innovent Biologics Corporation Information
Table 121. Innovent Biologics Description and Business Overview
Table 122. Innovent Biologics PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. Innovent Biologics PD-1 and PD-L1 Inhibitor Product
Table 124. Innovent Biologics Recent Developments/Updates
Table 125. Junshi Biosciences Corporation Information
Table 126. Junshi Biosciences Description and Business Overview
Table 127. Junshi Biosciences PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Junshi Biosciences PD-1 and PD-L1 Inhibitor Product
Table 129. Junshi Biosciences Recent Developments/Updates
Table 130. Akeso Corporation Information
Table 131. Akeso Description and Business Overview
Table 132. Akeso PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Akeso PD-1 and PD-L1 Inhibitor Product
Table 134. Akeso Recent Developments/Updates
Table 135. Alphamab Oncology Corporation Information
Table 136. Alphamab Oncology Description and Business Overview
Table 137. Alphamab Oncology PD-1 and PD-L1 Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. Alphamab Oncology PD-1 and PD-L1 Inhibitor Product
Table 139. Alphamab Oncology Recent Developments/Updates
Table 140. Key Raw Materials Lists
Table 141. Raw Materials Key Suppliers Lists
Table 142. PD-1 and PD-L1 Inhibitor Distributors List
Table 143. PD-1 and PD-L1 Inhibitor Customers List
Table 144. PD-1 and PD-L1 Inhibitor Market Trends
Table 145. PD-1 and PD-L1 Inhibitor Market Drivers
Table 146. PD-1 and PD-L1 Inhibitor Market Challenges
Table 147. PD-1 and PD-L1 Inhibitor Market Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of PD-1 and PD-L1 Inhibitor
Figure 2. Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global PD-1 and PD-L1 Inhibitor Market Share by Type in 2022 & 2034
Figure 4. Monoclonal Antibody Product Picture
Figure 5. Bispecific Antibody Product Picture
Figure 6. Global PD-1 and PD-L1 Inhibitor Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 7. Global PD-1 and PD-L1 Inhibitor Market Share by Application in 2022 & 2034
Figure 8. Lung Cancer
Figure 9. Stomach Cancer
Figure 10. Breast Cancer
Figure 11. Rectal Cancer
Figure 12. Others
Figure 13. Global PD-1 and PD-L1 Inhibitor Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 14. Global PD-1 and PD-L1 Inhibitor Market Size (2024-2034) & (US$ Million)
Figure 15. Global PD-1 and PD-L1 Inhibitor Sales (2024-2034) & (K Units)
Figure 16. Global PD-1 and PD-L1 Inhibitor Average Price (US$/Unit) & (2024-2034)
Figure 17. PD-1 and PD-L1 Inhibitor Report Years Considered
Figure 18. PD-1 and PD-L1 Inhibitor Sales Share by Manufacturers in 2022
Figure 19. Global PD-1 and PD-L1 Inhibitor Revenue Share by Manufacturers in 2022
Figure 20. The Global 5 and 10 Largest PD-1 and PD-L1 Inhibitor Players: Market Share by Revenue in 2022
Figure 21. PD-1 and PD-L1 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 22. Global PD-1 and PD-L1 Inhibitor Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 23. North America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2024-2034)
Figure 24. North America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2024-2034)
Figure 25. United States PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 26. Canada PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 27. Europe PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2024-2034)
Figure 28. Europe PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2024-2034)
Figure 29. Germany PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 30. France PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 31. U.K. PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. Italy PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. Russia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Asia Pacific PD-1 and PD-L1 Inhibitor Sales Market Share by Region (2024-2034)
Figure 35. Asia Pacific PD-1 and PD-L1 Inhibitor Revenue Market Share by Region (2024-2034)
Figure 36. China PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 37. Japan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 38. South Korea PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. India PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. Australia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. China Taiwan PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Southeast Asia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. Latin America PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2024-2034)
Figure 44. Latin America PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2024-2034)
Figure 45. Mexico PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 46. Brazil PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 47. Argentina PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Middle East & Africa PD-1 and PD-L1 Inhibitor Sales Market Share by Country (2024-2034)
Figure 49. Middle East & Africa PD-1 and PD-L1 Inhibitor Revenue Market Share by Country (2024-2034)
Figure 50. Turkey PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 51. Saudi Arabia PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 52. UAE PD-1 and PD-L1 Inhibitor Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. Global Sales Market Share of PD-1 and PD-L1 Inhibitor by Type (2024-2034)
Figure 54. Global Revenue Market Share of PD-1 and PD-L1 Inhibitor by Type (2024-2034)
Figure 55. Global PD-1 and PD-L1 Inhibitor Price (US$/Unit) by Type (2024-2034)
Figure 56. Global Sales Market Share of PD-1 and PD-L1 Inhibitor by Application (2024-2034)
Figure 57. Global Revenue Market Share of PD-1 and PD-L1 Inhibitor by Application (2024-2034)
Figure 58. Global PD-1 and PD-L1 Inhibitor Price (US$/Unit) by Application (2024-2034)
Figure 59. PD-1 and PD-L1 Inhibitor Value Chain
Figure 60. PD-1 and PD-L1 Inhibitor Production Process
Figure 61. Channels of Distribution (Direct Vs Distribution)
Figure 62. Distributors Profiles
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed